Jade Biosciences clinical trials we track

Check company identity source

Phase 3 1 trial

TrialDrugs studiedStatusPrimary completion
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07902817JADE101Recruiting2029-06Estimated

Phase 2 1 trial

TrialDrugs studiedStatusPrimary completion
A Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07541287JADE101Recruiting2029-01Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Safety and tolerability of JADE101 in participants with IgA nephropathy. After: Measure: Incidence of treatment-emergent adverse events (safety and tolerability).

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source